Evoke Pharma, Inc. Announces That EVK-001 Phase 2b Results Will Be Presented At Digestive Disease Week 2014
4/28/2014 9:11:57 AM
SOLANA BEACH, Calif., April 28, 2014 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (Nasdaq:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced that data from the Company's Phase 2b clinical trial of EVK-001, a novel intranasal formulation and delivery method of metoclopramide for diabetic female patients with symptoms associated with gastroparesis, was accepted for an oral presentation at Digestive Disease Week 2014 (DDW). DDW will take place May 3-6, 2014 in Chicago, Illinois.
Help employers find you! Check out all the jobs and post your resume.
comments powered by